EMEA-002031-PIP01-16

Key facts

Invented name
Active substance
Emapalumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0358/2017
PIP number
EMEA-002031-PIP01-16
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of haemophagocytic lymphohistiocytosis
Route(s) of administration
Intravenous use
Contact for public enquiries
Novimmune B.V.
Tel. +41 228397141
E-mail: pip@novimmune.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating